Clinical Trial

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study evaluates the safety, anti-tumor effect, and immunogenicity of Enoblituzumab given before radical prostatectomy. All patients will receive Enoblituzumab for 6 weekly doses beginning 50 days prior to radical prostatectomy.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2016-09-30; most recent amendment 2025-07-10.
Status change: Recruiting → Active, Not Recruiting 2019-09-19
Status change: Not Yet Recruiting → Recruiting 2017-06-22
Trial Details
NCT Number NCT02923180
Lead Sponsor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators: MacroGenics
Conditions Prostate Cancer
Enrollment 33 participants
Start Date 2017-02-14
Primary Completion 2020-08-11 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2025-07-22